论文部分内容阅读
重症肝炎的生存率仅为15～30%。类固醇激素疗法、高血糖素-胰岛素疗法,特殊成分的氨基酸输液和血浆交换等治疗已不能满足临床需要。目前统计,重症肝炎急性肝功不全中,甲乙型病毒性肝炎和醋氨酚中毒性肝炎近10年的生存率已提高到50%,但非甲非乙型肝炎和氟烷等药物性肝炎却毫无改善,其生存率仅为10%,后者为难治性肝炎,多呈亚急性经过,施行肝移植者,生存率提高到62.5%(10/16例)。Starzl 等报告,自引进环孢菌素 A 治疗以来,施行肝移植术者13例(13/29)存活7例,生存率为53.8%。未施行手术者16例,存活3例,生存率为18.8%。累积生存率(18月后)两组间也有显著差异。肝移植组
Severe hepatitis survival rate of only 15 to 30%. Steroid hormone therapy, glucagon - insulin therapy, special components of amino acid infusion and plasma exchange therapy has failed to meet clinical needs. The current statistics, severe hepatitis acute liver failure, hepatitis A and acetaminophen toxic hepatitis nearly 10-year survival rate has risen to 50%, but non-A non-hepatitis B and halothane and other drug-induced hepatitis Without any improvement, its survival rate was only 10%. The latter was refractory hepatitis, mostly subacute. The survival rate of liver transplant recipients increased to 62.5% (10/16 cases). Starzl et al. Reported that since the introduction of cyclosporin A, 13 (13/29) patients undergoing liver transplantation survived in 7 and the survival rate was 53.8%. 16 cases were not operated, 3 cases survived, the survival rate was 18.8%. The cumulative survival rate (after 18 months) was also significantly different between the two groups. Liver transplantation group